Last reviewed · How we verify

Potassium Acetate

Pfizer · FDA-approved approved Small molecule Quality 55/100

Potassium Acetate is a small molecule drug originally developed by B BRAUN and currently owned by Hospira. It is FDA-approved for the treatment of hypokalemia and prevention of hypokalemia. The commercial status of Potassium Acetate is off-patent, with two generic manufacturers available. Key safety considerations include the potential for hyperkalemia, a condition characterized by elevated potassium levels in the blood. As an off-patent medication, Potassium Acetate is widely available and used to treat hypokalemia.

At a glance

Generic namePotassium Acetate
SponsorPfizer
Drug classpotassium acetate
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved
First approval1971

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: